PREEMPT CRC Study
Colorectal Cancer Screening Validation
Phase 3/RegistrationalActive
Key Facts
Indication
Colorectal Cancer Screening Validation
Phase
Phase 3/Registrational
Status
Active
Company
About Freenome
Freenome is a pioneering diagnostics company developing a multiomics and AI-powered platform for early cancer detection via blood tests. Founded in 2014 and headquartered in South San Francisco, the company's lead program is a blood-based screening test for colorectal cancer (CRC), which is undergoing validation in the large-scale PREEMPT CRC study. Freenome is also expanding its pipeline into lung cancer detection and aims to create a broad, accessible screening platform to improve cancer outcomes through earlier intervention.
View full company profile